Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.

Rights plan protects the Company and its stockholders from a change of control without a control premium. Amended and Restated Bylaws ensure orderly and informed consent solicitat ...

The new updates to the tech-infused broker-dealer include the incorporation of artificial intelligence (AI) and an automated ...

A practical founder's guide to ADA website compliance, covering tools, timelines, real costs, WCAG 2.1 AA standards and how ...